NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

RecruitingNA

Sponsor: The University of Texas at Dallas

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Transcranial Direct Current Stimulation, Sham transcranial direct current stimulation

Countries: United States

The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

º Diagnosed with relapsing-remitting multiple sclerosis (RRMS)

º Memory retrieval deficit based on neuropsychological testing done in our lab

º Must be fluent in speaking and reading English.

Exclusion Criteria:

º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing

º Participants using benzodiazepines must have been on a stable dose for at least two months

º Potentially confounding psychological or neurological disorder, including:

* dementia of any type
* epilepsy or other seizure disorders
* severe traumatic brain injury
* brain tumor
* present drug abuse
* stroke
* blood vessel abnormalities in the brain
* Parkinson's disease
* Huntington's disease

º inability to give informed consent

º cranial implants

º skull defects that affect tDCS administration

º use of medications that interact with or potentially interact with tDCS effects, including:

* anti-convulsants
* L-dopa
* carbamazepine
* sulpiride
* pergolide
* lorazepam
* rivastigmine
* dextromethorphan
* D-cycloserine
* flunarizine
* ropinirole
* stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment

Locations (1)

Richardson, Texas, United States